UNSPSC 51241540: Phenylephrine/prednisolone/sulfacetamide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP900. This VA Drug Class (OP900) classifies this compound as belonging to the group OPHTHALMICS, OTHER.

UNSPSC 51241540 Phenylephrine/prednisolone/sulfacetamide is a Commodity code covering branded and generic ophthalmic combination products—specifically multi-ingredient eye drops containing decongestants, anti-inflammatories, and antibiotics—that state and local health systems, clinics, and correctional facilities procure for patient care. The code captures pharmaceutical supply contracts where state and local governments buy through cooperative purchasing vehicles and direct manufacturer relationships, with pricing, compliance documentation, and supply-chain integration as the primary procurement drivers.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, including Oregon. The solicitation seeks manufacturers to supply products identified by National Drug Code, with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026. Vendors must demonstrate cGMP and Drug Supply Chain Security Act compliance, maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), carry $5 million in commercial general liability insurance, and submit pricing in flat-price, net-price, or WAC-minus formats. Evaluation weighs price competitiveness at 75 percent, with lesser weight assigned to fixed pricing, administrative fee compliance, EDI capability, and administrative-fee acceptance. The contract term runs two years for new vendors with optional extensions, while incumbents' amendments extend through June 30, 2028. MMCAP reserves multi-award authority based on therapeutic considerations and member-specific needs.